|
Summary
2008, Vol. 24, No. 7, Pages 1919-1929
The effect of orlistat and ezetimibe, alone or in combination, on serum LDL and small dense LDL cholesterol levels in overweight and obese patients with hypercholesterolaemiaE. S. NakouaDepartment of Internal Medicine, Medical School, University of Ioannina, Ioannina, Greece bLaboratory of Physiology, Medical School, University of Ioannina, Ioannina, Greece cLaboratory of Biochemistry, Department of Chemistry, University of Ioannina, Ioannina, Greece dDepartment of Clinical Biochemistry, Royal Free Campus, University College London (UCL), London, UK ABSTRACT Background: Increased concentrations of low density lipoprotein cholesterol (LDL-C), as well as of small dense LDL-C (sdLDL-C), are considered as cardiovascular risk factors. Objective: An assessment of the effects of ezetimibe and orlistat administration, alone or in combination, on LDL-C and sdLDL-C levels (primary endpoint), as well as on anthropometric variables and metabolic parameters (secondary endpoints) in overweight and obese patients [body mass index (BMI) > 28 kg/m2] with hypercholesterolaemia [total cholesterol > 200 mg/dL (5.2 mmol/L)]. Methods: Eighty six subjects were prescribed a low-fat low-calorie diet and were randomly allocated to receive orlistat 120 mg, 3 times daily (O group), ezetimibe 10 mg/day (E group) or both (OE group) for 6 months. Results: Significant reductions in LDL-C (−19%, −21%, −32% in groups O, E and OE, respectively, all p < 0.01 vs. baseline) and sdLDL-C levels (−45%, −48%, −76% in groups O, E, OE, respectively, all p < 0.01 vs. baseline) were observed. Group OE experienced a significantly greater reduction in LDL-C and sdLDL-C levels compared with groups O and E (p < 0.05). Furthermore, significant reductions of BMI, homeostasis model assessment (HOMA) index, serum uric acid, transaminase activities and plasma lipoprotein-associated phospholipase A2 (Lp-PLA2) activity were observed in the O and OE groups. Gamma-glutamyl transpeptidase activity and Lp-PLA2 activity improved significantly more with the combination treatment compared with either orlistat or ezetimibe monotherapy. Conclusions: Orlistat and ezetimibe combination had a more favourable effect on LDL-C and sdLDL-C levels in overweight and obese hypercholesterolaemic patients than either drug alone. Furthermore, orlistat, alone or in combination with ezetimibe, additionally improved several anthropometric and metabolic variables. Forward Links to Citing ArticlesES Nakou, TD Filippatos, DN Kiortsis, CS Derdemezis, AD Tselepis, DP Mikhailidis, MS Elisaf. (2008) The effects of ezetimibe and orlistat, alone or in combination, on high-density lipoprotein (HDL) subclasses and HDL-associated enzyme activities in overweight and obese patients with hyperlipidaemia. Expert Opinion on Pharmacotherapy 9:18, 3151-3158 Online publication date: 1-Dec-2008. Summary | Full Text | PDF (241 KB) | PDF Plus (222 KB) M Florentin, EN Liberopoulos, TD Filippatos, C Kostara, A Tselepis, DP Mikhailidis, M Elisaf. (2008) Effect of rimonabant, micronised fenofibrate and their combination on cardiometabolic risk factors in overweight/obese patients: a pilot study. Expert Opinion on Pharmacotherapy 9:16, 2741-2750 Online publication date: 1-Nov-2008. Summary | Full Text | PDF (262 KB) | PDF Plus (249 KB) Users who read this article also read:
|
|
TOC Alert